2-(4-氯苯基)-2-甲基丙酰肼 | 1016557-75-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-氯苯基)-2-甲基丙酰肼
• 英文名称: 2-(4-chlorophenyl)-2-methylpropanehydrazide
• 英文别名: 2-methyl-2-(4-chlorophenyl)propanehydrazide
• CAS: 1016557-75-7
• 化学式: C₁₀H₁₃ClN₂O
• mdl: MFCD23096980
• 分子量: 212.679
• InChiKey: IIVXYBASXNEPOZ-UHFFFAOYSA-N

物化性质

• 熔点：
  85-86.4 °C(Solv: methanol (67-56-1))
• 沸点：
  390.5±25.0 °C(Predicted)
• 密度：
  1.196±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-氯苯基)-2-甲基丙酰肼 在 potassium hydroxide 、 肼 作用下， 以 甲醇 、 水 为溶剂， 反应 7.0h， 生成 4-amino-5-[2-(4-chlorophenyl)propan-2-yl]-4H-[1,2,4]-triazole-3-thiol
  参考文献：
  名称：

  合成，光谱表征和一系列新的6-芳基取代-3- [2-（4-取代的苯基）丙-2-基] -7-的生物评价ħ - [1,2,4]三唑并[3,4- b ] [1,3,4]噻二嗪

  摘要：

  由于已报道的三唑并噻二嗪具有抗癌活性，我们合成了一系列新的6-芳基取代的-3- [2-（4-取代的苯基）丙烷-2-基] -7H- [1,2,4]三唑[3] ，4- b ] [1,3,4]噻二嗪，并通过台盼蓝排除法和MTT法测试了体外细胞毒性。还评估了这些化合物的体内驱虫活性以及体外抗菌研究。在测试的化合物中，化合物7j是最有希望的细胞毒性剂，在MCF-7细胞中的IC 50值为10.54μM。化合物7l和7q表现出优异的驱虫活性。化合物7d，7f，7j，7l，7o，7p和7r显示出良好的抗菌活性，而化合物7e和7k显示出优异的抗真菌活性。通过IR，1 H NMR，13 C NMR和LCMS分析表征新合成的化合物的结构。

  DOI：

  10.1016/j.ejmech.2012.06.059
• 作为产物：
  描述：

  2-(4-氯苯基)-2-甲基丙酸甲酯 在 肼 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以77%的产率得到2-(4-氯苯基)-2-甲基丙酰肼
  参考文献：
  名称：

  合成，光谱表征和一系列新的6-芳基取代-3- [2-（4-取代的苯基）丙-2-基] -7-的生物评价ħ - [1,2,4]三唑并[3,4- b ] [1,3,4]噻二嗪

  摘要：

  由于已报道的三唑并噻二嗪具有抗癌活性，我们合成了一系列新的6-芳基取代的-3- [2-（4-取代的苯基）丙烷-2-基] -7H- [1,2,4]三唑[3] ，4- b ] [1,3,4]噻二嗪，并通过台盼蓝排除法和MTT法测试了体外细胞毒性。还评估了这些化合物的体内驱虫活性以及体外抗菌研究。在测试的化合物中，化合物7j是最有希望的细胞毒性剂，在MCF-7细胞中的IC 50值为10.54μM。化合物7l和7q表现出优异的驱虫活性。化合物7d，7f，7j，7l，7o，7p和7r显示出良好的抗菌活性，而化合物7e和7k显示出优异的抗真菌活性。通过IR，1 H NMR，13 C NMR和LCMS分析表征新合成的化合物的结构。

  DOI：

  10.1016/j.ejmech.2012.06.059

文献信息

• SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Abelman Matthew

  公开号：US20100125091A1

  公开（公告）日：2010-05-20

  The present invention relates to sodium channel inhibitors of Formula (I): in which R 1 , R 2 , R 3 , R 4 , R 5 , X, Y, and Z are as defined herein, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

  本发明涉及具有以下结构的钠通道抑制剂（I）：其中R1、R2、R3、R4、R5、X、Y和Z如本文所定义，并且其在治疗各种疾病状态中的使用，包括心血管疾病和糖尿病。该发明还涉及制备这些化合物的方法，以及含有这些化合物的药物组合物。
• Substituted heterocyclic compounds as ion channel modulators
  申请人：Gilead Sciences, Inc.

  公开号：US08664399B2

  公开（公告）日：2014-03-04

  The present invention relates to sodium channel inhibitors of Formula (I): in which R1, R2, R3, R4, R5, X, Y, and Z are as defined herein, and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.

  本发明涉及式(I)的钠通道抑制剂：其中R1，R2，R3，R4，R5，X，Y和Z如本文所定义，并且其在治疗各种疾病状态中的使用，包括心血管疾病和糖尿病。该发明还涉及制备这些化合物的方法，以及含有这些化合物的制药组合物。
• Biarylpyrazolyl Oxadiazole as Potent, Selective, Orally Bioavailable Cannabinoid-1 Receptor Antagonists for the Treatment of Obesity
  作者：Suk Ho Lee、Hee Jeong Seo、Sung-Han Lee、Myung Eun Jung、Ji-Hyun Park、Hyun-Ju Park、Jakyung Yoo、Hoseop Yun、Jooran Na、Suk Youn Kang、Kwang-Seop Song、Min-ah Kim、Chong-Hwan Chang、Jeongmin Kim、Jinhwa Lee

  DOI：10.1021/jm800843r

  日期：2008.11.27

  Since the CB1 cannabinoid receptor antagonist 1 (SR141716, rimonabant) was previously reported to modulate food intake, CB1 antagonism has been considered as a new therapeutic target for the treatment of obesity. In the present study, biarylpyrazole analogues based on a pyrazole core coupled with 1,3,4-oxadiazole were synthesized and tested for CB1 receptor binding affinity. Thorough SAR studies to optimize pyrazole substituents as well as 1,3,4-oxadiazole ring led to several novel CB1 antagonists with IC50 similar to 1 nM for the CB1 receptor binding. Among these analogues, we identified 2-(4-((1H-1,2,4-triazol-1-yl)methyl)-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl)-5-(1-(trifluoromethyl)cyclopropyl)-1,3,4-oxa- diazole 43c as a promising precandidate for the development as an antiobesity agent.
• Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners
  作者：Junwon Lee、Sung-Han Lee、Hee Jeong Seo、Eun-Jung Son、Suk Ho Lee、Myung Eun Jung、MinWoo Lee、Ho-Kyun Han、Jeongmin Kim、Jahyo Kang、Jinhwa Lee

  DOI：10.1016/j.bmc.2010.01.073

  日期：2010.3

  Novel C-aryl glucoside SGLT2 inhibitors containing 1,3,4-thiadiazole moieties were designed and synthesized. Among the compounds tested, biaryl-type compounds containing pyrazine 59, 2-furan 61, and 3-thiophene 71 showed the best in vitro inhibitory activities to date (IC50 = 3.51-7.03 nM) against SGLT2. A selected compound 61, demonstrated reasonable blood glucose-lowering effects, indicating that the information obtained from the SAR studies in this 1,3,4-thiadiazolylmethylphenyl glucoside series might help to design more active SGLT2 inhibitors that are structurally related. (C) 2010 Elsevier Ltd. All rights reserved.
• Synthesis and biological activities of a novel series of 3,6-disubstituted-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazoles containing gem-dimethylbenzyl moiety
  作者：Pushpan Puthiyapurayil、Boja Poojary、Sunil Kumar、Raveendra Hunnur

  DOI：10.1002/jhet.674

  日期：2011.9

  AbstractA novel series of 3,6‐disubstituted‐1,2,4‐triazolo‐[3,4‐b]‐1,3,4‐thiadiazoles (6a–r) containing gem‐dimethyl benzyl moiety were prepared by the condensation of 4‐amino‐3‐aryl/aralkyl substituted‐5‐mercapto‐1,2,4‐triazoles (5a, 5b, 5c) with various fluoro substituted aromatic acids in the presence of POCl3. IR, 1H NMR, 13C NMR, 2D NMR (COSY), and mass spectral data confirmed the structures of all the synthesized compounds. All the compounds were also screened for their antibacterial, antifungal and analgesic activities. Compounds 6b, 6d, 6f, 6g, 6h, 6i, 6m, 6n, 6o, 6p, and 6r exhibited promising antibacterial and compounds 6a, 6d, 6f, 6g, 6h, 6k, 6m, 6o, 6p, and 6q showed significant analgesic activities. J. Heterocyclic Chem., (2011)